Company* (Country; Symbol) | Product | Description | Indication | Status (Date) | |
AUTOIMMUNE | |||||
Anesiva Inc. (ANSV) | Adlea | Long-acting, non-opioid candidate | Osteoarthritis | Phase II data showed that a 1 mg treatment produced substantial reductions in pain that persisted for up to 12 weeks (7/2) | |
Barrier Therapeutics Inc. (BTRX) | Rambazole | Oral; a retinoic acid metabolism-blocking agent | Moderate to severe psoriasis | Phase II showed the drug was well tolerated; the company selected the 2-mg dose for further development (7/12) | |
BioCryst Pharmaceuticals Inc. (BCRX) | BCX-4208 | An orally available small-molecule inhibitor of purine nucleoside phos-phorylase | Plaque psoriasis | Started a Phase II study (7/17) | |
Genzyme Corp. (GENZ) | Hylastan | An injected joint lubricator | Osteoarthritis knee pain | Pivotal study showed hylastan failed to beat steroids (7/5) | |
Medarex Inc. (MEDX) and Novartis Pharma AG (Switzerland) | ACZ885 | A fully human anti-IL-1 beta antibody | Muckle Wells syndrome | Advanced it into a Phase III trial (7/18) | |
MedImmune Inc. (LSE:MDI; unit of AstraZeneca plc; UK) | MEDI-545 | A fully human monoclonal antibody targeting interferon-alpha | Systemic lupus erythematosus | Began dosing patients in a Phase Ib trial (7/19) | |
CANCER | |||||
Antisoma plc (UK; LSE:ASM) | ASA404 | Small-molecule vascular disrupting agent designed to target blood vessels that nourish tumors | Recurrent, platinum-sensitive ovarian cancer | Phase II failed to meet its end-points (7/12) | |
Avalon Pharmaceuticals Inc. (AVRX) | AVN944 | A small-molecule inhibitor of inosine monosphospate dehydrogenase | Pancreatic cancer | Started a Phase II trial (7/12) | |
Cell Genesys Inc. (CEGE) | GVAX | Immunotherapeutic | Prostate cancer | Completed enrollment in its VITAL-1 Phase III trial (7/10) | |
Cell Therapeutics Inc. (CTIC) | Pixantrone | An anthracenedione | Non-Hodgkin's lymphoma | Interim Phase II/III data indicated pixantrone-based combination therapy resulted in complete or partial responses (7/11) | |
Cougar Biotechnology Inc. (OTC BB: CGRB) | CB7630 | Abiraterone acetate | Prostate cancer | Phase I and Phase II data showed that 87% of patients experienced a decline in prostate specific antigen levels with 61% experiencing a confirmed decline in PSA levels of greater than 50% (7/9) | |
Expression Genetics Inc.* | EGEN-001 | Formulated using the company's TheraPlas delivery technology; composed of interleukin-12 gene expresion plasmid and a biocompatible delivery polymer | Recurrent epithelial ovarian cancer | Started a Phase In a study of EGEN-001 in combination with standard chemotherapy (7/20) | |
Genaera Corp. (GENR) | Evizon | Squalamine lactate; anti-angiogenesis agent; vas-cular endothelial growth factor inhibitor | Prostate cancer | Company discontinued the program (7/5) | |
Genzyme Corp. (GENZ) | Mozobil | Plerixafor | Non-Hodgkin's lymphoma | Phase III showed 59% of patients reated with Mozobil in combination with standard-of-care granulocyte-colony stimulating factor achieved the target thresh-old for collection of at least 5M CD34+cells/kg from the peripheral blood, compared with 20% of patients in the G-CSF and placebo group (7/19) | |
Geron Corp. (GERN) | GRN163L | Telomerase inhibitor | Advanced non- small-cell lung cancer | Began a Phase I/II trial (7/9) | |
Geron Corp. (GERN) | GRNVAC1 | Telomerase cancer vaccine | Acute myelog-enous leukemia | Started a Phase I/II trial (7/11) | |
GTx Inc. (GTXI) | Ostarine | Selective androgen receptor modulator | Cancer cachexia | Started a Phase IIb trial (7/3) | |
Halozyme Therapeutics Inc. (HALO) | Enhanze | An enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase or rHuPH20 | Cancer | In a 15-patient trial, injection of rHuPH20 with Humira showed it was well tolerated at all dose levels, without dose-limiting toxicity, premature withdrawals or serious adverse events (7/10) | |
ImClone Systems Inc. (IMCL) | Erbitux (FDA- approved) | Cetuximab | Non-small-cell lung cancer | Phase III trial missed the primary endpoint of progression-free survival in the 600-patient study, though secondary endpoints in-cluding response rate were achieved (7/12) | |
ImClone Systems Inc. (IMCL) | IMC-A12 | A monoclonal antibody targeting insulin-like growth factor-1 receptor | Metastatic colorectal cancer | Started a Phase II trial with 40 to 72 patients who are refractory to treatment with Erbitux (7/13) | |
Javelin Pharmaceuticals Inc. (AMEX:JAV) | PMI-150 | Intranasal ketamine | Breakthrough cancer pain | Started a Phase III trial (7/31) | |
Kiadis Pharma BV* (the Netherlands) | ATIR | Small molecule aimed at allowing blood cancer patients to receive bone marrow transplants without requiring access to a matched donor | Blood cancer | The U.S. National Institutes of Health is beginning a Phase II trial (7/9) | |
Light Sciences Oncology Inc.* | Litx | Light infusion therapy that uses light-emitting diodes to activate LS11 (talaporfin sodium) | Colorectal cancer metastatic to the liver | Treated the first patient in a Phase III trial (7/17) | |
Maxygen Inc. (MAXY) | MAXY-G34 | Pegylated form of granulo-cyte-colony stimulating factor | Chemotherapy-induced neutropenia | Started a Phase IIa trial (7/2) | |
MethylGene Inc. (Canada; TSX:MYG) and Pharmion Corp. (PHRM) | MGCD0103 | Isotype-specific histone deacetylase inhibitor product candidate | Refractory chronic lympho-cytic leukemia | Started a single-agent Phase II trial with up to 40 patients (7/12) | |
Millennium Pharmaceuticals Inc. (MLNM) | Velcade- based therapy | Bortezomib; proteasome inhibitor | Multiple myeloma | An induction therapy prior to stem cell transplantation produced a high complete remission/complete response rate of 20% (7/2); began a Phase III trial comparing Velcade, dexamethasone; Velcade, thalidomide anddexamethasone; and Velcade, melphalan and prednisone (7/16) | |
OncoGenex Technologies Inc.* and Isis Pharmaceuticals Inc. (ISIS) | OGX-011 | Second-generation anti-sense drug designed to inhibit the production of clusterin, a cell survival protein | Metastatic hormone refractory prostate cancer | Phase II data showed that OGX-011 plus docetaxel achieved improved survival, longer progression-free survival, and more frequent decreases in prostate-specific antigen levels than patients receiving OGX-011 plus mitoxantrone (7/31) | |
Oncolytics Biotech Inc. (Canada; ONCY) | Reolysin | A formulation of the human reovirus | Sarcomas that have metast-asized to the lung | Enrolled the first two patients in a Phase II study (7/20) | |
OxiGene Inc. (OXGN) | Zybrestat | Combretastatin-A4 phosphate/CA4P | Metastatic anaplastic thyroid cancer | Began a pivotal registration study with 180 patients (7/9) | |
Peplin Ltd. (Australia; ASX:PEP) | PEP005 | Topical agent designed to kill cancer cells and stimulate an immune response | Actinic keratosis | Phase IIb data indicate the drug was well tolerated, with no serious adverse events, and resulted in statistically significant lesion clearance at all doses tested (7/19) | |
Poniard Pharmaceuticals Inc. (PARD) | Picoplatin | Intravenous picoplatin; a new generation platinum chemotherapy agent | Metastatic hormone-refractory prostate cancer | Started a Phase II trial in combination with docetaxel (7/31) | |
ProMetic Life Sciences Inc. (Canada; TSX:PLI) | PBI-1402 | Orally active, low molecular weight synthetic compound | Chemotherapy-induced anemia | Phase Ib/II data confirmed clinical activity (7/10) | |
Pro- Pharmaceuticals Inc. (AMEX:PRW) | Davanat | Carbohydrate compound designed for targeted delivery | Metastatic colorectal cancer | Provided data from eight patients in a Phase II trial showing two had tumor shrinkage of greater than 30% (7/9) | |
Pro- Pharmaceuticals Inc. (AMEX:PRW) | Davanat | Carbohydrate compound designed for targeted delivery | Advanced bile duct and gall-bladder cancers | Began dosing patients in a Phase II trial of Davanat with 5-Fluorouracil (7/25) | |
Protox Therapeutics Inc. (Canada; CDNX:PRX) | PRX302 | Proaerolysin-based | Prostate cancer | Top-line Phase I data indicated it was well tolerated, with no significant adverse events (7/10) | |
Rigel Pharmaceuticals Inc. (RIGL) and Merck KGaA (Germany) | R763/ AS703569 | A highly potent, orally available Aurora kinase inhibitor | Advanced malignancies | Began enrolling patients in a Phase I study (7/12) | |
SuperGen Inc. (SUPG) | MP470 | Oral, multitargeted tyrosine kinase inhibitor | Advanced-stage solid tumors | Dosed the first patient in a Phase I trial (7/5) | |
Threshold Pharmaceuticals Inc. (THLD) | TH-302 | First hypoxia-activated prodrug | Advanced solid tumors | Started a Phase I trial (7/26) | |
Tracon Pharmaceuticals Inc.* | TRC093 | A first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen | Cancer | Started treatment in a Phase I trial (7/11) | |
Trion Pharma GmbH* (Germany) and Fresenius Group (Germany) | Removab | Catumaxomab; a tri-functional antibody de-signed to bind both T cells and epithelial cell adhesion molecule | Malignantascites | Phase II/III data showed it significantly increased time to tumor progression and had a positive influence on overall survival time (7/17) | |
YM BioSciences Inc. (Canada; AMEX:YMI) | Nimotuzumab | A humanized monoclonal antibody that targets the epidermal growth factor receptor | Colorectal cancer | Enrolled the first patients in a 50-patient initial cohort of its Phase II trial of nimotuzumab in combination with irinotecan (7/31) | |
Ziopharm Oncology Inc. (ZIOP) | ZIO-201 | Isophosphoramide mustard | Advanced sarcoma | Phase II data showed one of 10 patients had a partial response and four have stable disease (7/11) | |
CARDIOVASCULAR | |||||
Ablynx* (Belgium) | ALX-0081 | An anti-thrombic; a first-in-class nanobody | Acute coronary syndrome | Phase I data showed the desired pharmacodynamic effect was observed and ALX-0081 was well tolerated and showed no serious adverse events or dose limiting toxicity (7/2) | |
Amira Pharmaceuticals Inc.* | AM103 | An oral, next-generation inhibitor of the 5-lipoxy-genase-activating protein | Asthma and cardiovascular disease | Phase I data showed that a single dose achieves highly significant inhibition of leukotriene synthesis (7/16) | |
Arena Pharmaceuticals Inc. (ARNA) | APD791 | An oral agent; a selective inverse agonist of the 5-HT2A serotonin | Arterial throm-boembolic diseases | Started dosing in a Phase I trial (7/18) | |
Depomed Inc. (DEPO) | Gabapentin GR | Targets GABA receptors in the brain | Postherpetic neuralgia | Top-line data from a Phase III, 407-patient study showed it hit statistical significance in daily pain scores in the first six weeks when dosed once daily, and in the first five weeks when dosed twice daily; the mean reductions in average scores from baseline were 1.83 (in the once-daily arm), 1.72(twice daily) and 1.43 (placebo) (7/10) | |
DiaDexus Inc.* | LP-PLA2 | Lipoprotein-associated phospholipase A2, an indicator of vascular inflammation | To identify people at high risk for ischemic stroke | Study results indicate that LP-PLA2 provides information over and above traditional risk factors to help identify individuals at the highest risk for ischemic stroke (7/5) | |
LifeCycle Pharma (Denmark; CSE:LCP) | LCP-AtorFen | A fixed-dose combination of atorvastatin and fenofibrate | High cholesterol levels | Initiated a Phase II trial (7/12) | |
Medicure Inc. (Canada; TSX:MPH) | Aggrastat (FDA-approved) | Tirofiban hydrochloride; glycoprotein | Heart attack; patients under- going high-risk percutaneous coronary intervention | Follow-up data showed patients treated with Aggrastat plus a sirolimus-eluting stent had sig-nificantly lower cumulative incidence of death, myocardial infarction or target vessel revas-cularization than patients receiving Reopro plus a bare-metal stent (7/11) | |
Portola Pharmaceuticals Inc.* | PRT054021 | An oral Factor Xa inhibitor | To prevent venous thrombo-embolic events in patients under-going total knee replacement | Phase II data showed that the incidence of VTE was 20%, 15% and 10% in the low-dose group, the high-dose group, and the enoxaparin group, respectively (7/11) | |
Sygnis Pharma AG (Germany; FSE:LIO) | AX200 | Designed to stop neuronal cell death in the acute phase of stroke | Stroke | Safety and tolerability were demonstrated in a 44-patient Phase IIa study (7/23) | |
Talecris Bio- therapeutics Inc.* | TAL-05-00018 (Plasmin) | Human plasma-derived thrombolytic | Peripheral arterial occlusion | Phase I data showed the dose-related thrombolytic effect of Plasmin without an increase in dose-related adverse events (7/11) | |
Tranzyme Pharma Inc.* | TZP-101 | A ghrelin agonist | Postoperativeileus | Started a Phase IIb trial (7/26) | |
CENTRAL NERVOUS SYSTEM | |||||
Adolor Corp. (ADLR) | ADL5859 | A novel delta opioid agonist | Pain | Began a Phase II study (7/9) | |
Affiris* (Austria) | Affitope AD01 | Alzheimer's vaccine | Alzheimer's disease | Started a Phase I trial (7/19) | |
Alkermes Inc. (ALKS) | ALKS 29 | Oral compound | Alcohol dependence | Preliminary results from a Phase I/II trial showed statistically significant improvement compared to placebo in percent of days abstinent, percent of heavy drinking days and average number of drinks per day (7/2) | |
BioLineRx Ltd.* (Israel) | BL-1020 | The first GABA enhanced antipsychotic | Schizophrenia | Completed a study showing it blocks dopamine receptors in the human brain (7/17) | |
Catalyst Pharmaceutical Partners Inc. (CPRX) | CPP-109 | Vigabatrin; an orally administered, small-molecule compound designed to inhibit psychostimulant-in-duced dopamine release | Cocaine dependence | Started a Phase II trial (7/10) | |
Cortex Pharmaceuticals Inc. (AMEX:COR) | CX717 | An ampakine compound designed to enhance memory and cognition | Alzheimer's disease | FDA said it could resume enrollment in the Alzheimer's positron emission tomography scan study at all requested dose levels (7/17) | |
Durect Corp. (DRRX) | Posidur | Long-acting local anesthetic administered during surgery, where it releases therapeutic levels of bupivacaine | Postoperative pain in patients undergoing inguinal hernia repair | A Phase IIb trial demonstrated statistically significant reductions in pain and total consumption of supplemental opioid analgesic medications vs. placebo (7/17) | |
Genzyme Corp. (GENZ) | Carticel | Autologous cultured chondrocytes | Knee pain | Clinical data showed significant reductions in knee pain, as well as improvements in function, in-cluding recreational and sports activities (7/16) | |
Incyte Corp. (INCY) | INCB9471 | An oral CCR5 antagonist designed to block the virus from entering uninfected cells | HIV | Phase IIa results demonstrated that it provided a significant decline in viral load when used as a monotherapy in 19 patients (7/24) | |
Intellect Neuro- sciences Inc. (OTC BB:ILNS) | Oxigon | A chemically synthesized form of a small, naturally occurring molecule that has unique anti-fibrillo-genic, neuroprotectant and antioxidant properties | Alzheimer's diseases | Phase Ia results showed no serious adverse effects in any of the subjects throughout the dose levels (7/30) | |
Javelin Pharmaceuticals Inc. (AMEX:JAV) | Dyloject | Diclofenac sodium; an injectable nonsteroidal anti-inflammatory drug | Postoperative pain | Began treating patients in the second of two planned Phase III studies (7/26) | |
Lexicon Pharmaceuticals Inc. (LXRX) | LX6171 | Oral drug candidate | Cognitive disorders | Successfully completed Phase I trials; it proved to be well tolerated at all dose levels with systemic exposure described as "excellent" (7/31) | |
Manhattan Pharmaceuticals Inc. (AMEX:MHA) | Oleoylestrone | Oral therapy; synthetic formulation | Obesity | Each of two Phase IIa trials failed to demonstrate statistically or clinically meaningful weight loss vs. placebo (7/10) | |
Memory Pharmaceuticals Corp. (MEMY) | MEM 3454 | A nicotinic alpha-7 receptor partial agonist | Alzheimer's disease | Completed enrollment of a targeted 80 patients in a Phase IIa trial (7/13) | |
Orexigen Therapeutics Inc. (OREX) | Empatic | A drug that combines the sustained formulations of epilepsy drug zondisamide plus the antidepressant buproprion | Obesity | Phase IIb demonstrated statistically significant weight loss vs. placebo (7/24) | |
Pipex Pharmaceuticals Inc. (OTC BB: PPXP) | Trimesta | Estriol | Multiple sclerosis | Started dosing in a Phase II/III trial for women with relapsing- remitting MS (7/17) | |
Targacept Inc. (TRGT) | TC-5619 | A small molecule designed to modulate the activity of the neuronal nicotinic receptor subtype known as alpha7 | Schizophrenia/cognitive impairment/ inflammation | Started a Phase I trial with healthy volunteers (7/26) | |
YM BioSciences Inc. (Canada; AMEX:YMI) | AeroLEF | An inhaled-delivery, composition of free and lipo-some-encapsulated Fentanyl | Pain | For the first dose administered, 59% reported a pain intensity score of less than or equal to 1, compared to 27% of placebo patients (7/11) | |
DIABETES | |||||
Metabasis Therapeutics Inc. (MBRX) | CS-917 | Inhibits gluconeogenesis | Diabetes | It failed a Phase IIb trial (7/17) | |
Metabolex Inc.* | MBX-102 | JNJ 39659100; an insulin sensitizer | Type II diabetes | Completed enrollment in the 400-patient Phase II/III trial (7/19) | |
Sirtris Pharmaceuticals Inc. (SIRT) | SRT501 | Agent that targets SIRT1, a member of the human sirtuin family of enzymes | Type II diabetes | Phase Ia data showed SRT501 had an improved exposure in terms of curve and maximal concentrations when compared to resveratrol (7/17) | |
XOMA Ltd. (XOMA) | XOMA 052 | A monoclonal antibody targeting interleukin-1 beta | Type II diabetes | Started Phase I testing (7/16) | |
INFECTION | |||||
Acambis plc (UK; LSE:ACM) | ACAM-FLU-A | Vaccine designed to target all A strains of the influenza virus | Influenza | Started a Phase I trial (7/24) | |
Advanced Life Sciences Holdings Inc. (ADLS) | Cethromycin | A once-a-day antibiotic | Community-acquired pneumonia | Supplemental efficacy data confirmed it met its non-inferiority endpoint in a Phase III trial (7/2) | |
AlphaVax Inc.* | Influenza vaccine based on the company's replicon vector technology | Influenza | Interim Phase I data showed the vaccine is safe and well tolerated (7/30) | ||
Anadys Pharmaceuticals Inc. (ANDS) and Novartis Pharma AG (Switzerland) | ANA975 | Oral prodrug of isatoribine, a Toll-like receptor-7 agonist | Hepatitis C virus infection | Companies decided to discontinue development because results to date do not support further clinical evaluation (7/27) | |
Arpida Ltd. (Switzerland; SWX:ARPN) | Iclaprim | Antibiotic; an intravenous new member of the diamino-pyrimidine class | Complicated skin and skin structure infections | Phase III trials showed it met the primary endpoint of non-inferiority to Pfizer Inc.'s Zyvox (7/16) | |
Avant Immuno- therapeutics Inc. (AVAN) | Ty800 | Single-dose, oral vaccine | Typhoid fever | Started enrolling 180 healthy volunteers in a Phase II study (7/30) | |
Avexa Ltd. (Australia; ASX:AVX) | ATC | Apricitabine; a cytidine analogue, an inhibitor of HIV reverse transcriptase | HIV | Phase IIb data showed that ATC demonstrated significant clinical activity against a range of drug-resistant HIV, including HIV strains harboring the lamivudine-resistance mutation (7/26) | |
BioCryst Pharmaceuticals Inc. (BCRX) | Peramivir | Influenza neuraminidase inhibitor | Influenza | Started a Phase II trial in hospitalized patients (7/24) | |
Biolex Therapeutics Inc.* and OctoPlus NV (the Netherlands; AMSTERDAM:OCTO) | Locteron | A controlled-release interferon alpha product | Chronic hepatitis C | Phase IIa data of Locteron in combination with ribavirin showed an early virologic re- sponse in 100% of patients treated (7/26) | |
Biota Holdings Ltd. (Australia; ASX:BTA) and MedImmune Inc. (LSE:MDI; unit of AstraZeneca plc; UK) | BTA9881 | Antiviral drug | Respiratory syncytical virus | Began a Phase Ia trial (7/17) | |
Genzyme Corp. (GENZ) | Tolevamer | Clostridium-difficile-toxin binder | Clostridium-difficile associated diarrhea | It failed to beat the standard prescribed oral dose of the antibiotic vancomycin in the first of two Phase III trials (7/6) | |
Gilead Sciences Inc. (GILD) | Truvada (FDA- approved) | Emtricitabine and tenofovir disoproxil fumarate | HIV | Phase III data showed 71% of Truvada/Sustiva patients compared to 58% of Combivir/Sustiva patients achieved and maintained viral load less than 400 copies/mL (7/23) | |
MedImmune Inc. (LSE:MDI) | RSV/PIV-3 | Vaccine | Respiratory syncytial virus and parainflu-enza virus Type 3 infections | Began dosing in a Phase I trial (7/3) | |
Monogram Biosciences Inc. (MGRM) and Pfizer Inc. | Maraviroc | A CCR5 antagonist | CCR5-tropic HIV-1 | Phase III data showed rates of virologic suppression were 70.6% compared to 73.1% in the efavirenz group for less than 400 copies/mL, and 65.3% vs. 69.3% at less than 50 copies/mL (7/25) | |
Novavax Inc. (NVAX) | Virus-like particle-based pandemic influenza vaccine | Influenza | Began vaccinating healthy volunteers in a Phase I/IIa trial (7/31) | ||
Nventa Bio- pharmaceuticals Corp. (TSX:NVN) | HspE7 | Vaccine for human papillomavirus-related diseases | High-grade cervical intra-epithelial neoplasia | Phase II data showed 95% of patients had disease regression or their disease remained stable (7/23) | |
Orchestra Therapeutics Inc. (OTC BB:OCHT) | IR103 | Second-generation HIV vaccine | HIV | Company discontinued development because Phase II data did not show a clear advantage over its original whole-killed HIV vaccine, Remune (7/18) | |
Pharmaxis Ltd. (Australia; PXSL) | Bronchitol | Inhalable dry powder formulation of mannitol delivered twice daily | Bronchiectasis | All 362 patients have completed the efficacy phase of its global Phase III trial (7/5) | |
Photopharmica Holdings Ltd.* (UK) | PPA 904 | A member of the phenothiazinium family of photosensitizers; topical photodynamic therapy | Microbial disease in wounds | Successfully completed a Phase II trial; it achieved a statistically significant reduction in the bacterial load of chronic leg ulcers and diabetic foot ulcers compared to placebo (7/10) | |
Polydex Pharmaceuticals Ltd. (Canada; POLXF) | Ushercell | A potential microbicide also known as cellulose sulfate | HIV | Phase III data showed there were more seroconversions in the Ushercell group than the placebo group, but not at a statistically significant level (7/25) | |
Progenics Pharmaceuticals Inc. (PGNX) | PRO140 | CCR5 humanized mono-clonal antibody | HIV | Phase Ib data showed dose dependent and statistically significant viral load reductions (7/25) | |
Repros Therapeutics Inc. (RPRX) | Proellex | Progesterone receptor modulator | Uterine fibroids and endometri-osis | New data showed patients exposed to the drug for up to six months demonstrated a benign endometrium based on the biopsies (7/26) | |
Samaritan Pharmaceuticals Inc. (AMEX:LIV) | SP-01A | Oral HIV entry inhibitor | HIV | Phase IIb data showed a reduction in the amount of viral infection in the blood of those taking SP-01A (7/20) | |
Starpharma Holdings Ltd. (Australia; ASX:SPL) | VivaGel | SPL7013 Gel; vaginal microbicide | To prevent HIV and vaginal herpes | Began a U.S. trial (7/11); results show it was well tolerated in men when applied topically once daily for seven days and left in place for nine hours (7/24) | |
Theratechnologies Inc. (Canada; TSX:TH) | TH9507 | A stabilized analogue of the growth hormone-releasing factor | HIV-associated lipodystrophy | Phase III data showed that patients treated with 2 mg daily of TH9507 significantly improved their perception of belly image compared to the placebo group (7/18) | |
Theravance Inc. (THRX) | TD-1792 | Heterodimer antibiotic | Complicated skin and skin structure infections | A Phase II trial met its primary endpoint of non-inferiority to vancomycin (7/10) | |
Tibotec Pharmaceuticals Ltd.* (Ireland) | Prezista | (Darunavir)/ritonavir | HIV | Phase III data showed that 77% of treatment-experienced patients taking Prezista with an optimized background regimen of antiretroviral agents, reached a viral load of less than 400 copies/mL at week 48, compared to 68% of patients taking lopinavir/ritonavir with OBR (7/6) | |
Trimeris Inc. (TRMS) and F. Hoffmann-La Roche Ltd. (Switzerland) | Fuzeon (FDA-approved) | Enfuvirtide | HIV | Started patient dosing in a trial to test Fuzeon in combination with an investigational integrase inhibitor (7/17); data showed Fuzeon used with darunavir/ritonavir achieved undetectable HIV of less than 50 copies per mL of blood in 64% of treatment experienced patients (7/23) | |
Vertex Pharmaceuticals Inc. (VRTX) | Reyataz | Atazanavir | HIV | A head-to-head study with Glaxo-SmithKline plc's Lexiva showed similar efficacy and lipid effects (7/25) | |
Vical Inc. (VICL) | ----- | DNA vaccine | Cytomegalovirus | Began enrollment of the 20th hematopoietic stem cell transplant recipient in the company's Phase II trial (7/11) | |
ViroPharma Inc. (VPHM) | Camvia | Maribavir; anti-CMV agent | To prevent cytomegalovirus in patients under-going liver transplantations | Company began a second Phase III trial to evaluate it against oral ganciclovir (7/5) | |
MISCELLANEOUS | |||||
Advanced Magnetics Inc. (AMAG) | Ferumoxytol | Intravenous iron replacement therapy | Chronic kidney disease | Phase III data showed statistically significant improvement vs. oral iron on the primary end-point of increased hemoglobin levels (7/23) | |
BioMimetic Therapeutics Inc. (BMTI) | GEM OS1 Bone Graft | Combines recombinant platelet-derived growth factor with a synthetic bone matrix, beta tri-calcium phosphate | Foot and ankle indications | A 20-patient pilot trial showed that 39% of patients receiving GEM OS1 exhibited fusion, as defined by osseous bridging of greater than 50% of the joint surface, compared to 33% of autograft patients at six weeks (7/13) | |
Cobalis Corp. (OTC BB:CLSC) | PreHistin | Agent designed to modulate levels of IgE, reducing the over-production of histamines | Hay fever | Two Phase III trials showed very low symptom levels in both placebo and drug groups, failing to hit statistical significance in the primary endpoint (7/6) | |
Cytos Biotechnology AG (Switzerland;SWX:CYTN) | CYT003- QbG10 sequence | Virus-like particle packaged with an immunostimulatory | Atopic dermatitis | It was well tolerated in a Phase IIa trial (7/3) | |
DOR BioPharma Inc. (OTC BB: DORB) | orBec | Oral beclomethasone dipropionate | To prevent acute graft-vs.-host disease after allogeneic hematopoietic cell transplantation | Started patient enrollment in a Phase II trial with up to 138 patients (7/12) | |
Endo Pharmaceuticals Inc. (ENDP) | Ketoprofen patch | Soft-tissue injuries | Two Phase III trials failed to demonstrate efficacy (7/12) | ||
Genaera Corp. (GENR) | Lomucin | Talniflumate; anti-inflammatory drug with activity against the hCLCA1 chloride channel | Cystic fibrosis | Company discontinued the program (7/5) | |
Hollis-Eden Pharmaceuticals Inc. (HEPH) | HE3286 | Orally bioavailable small-molecule adrenal steroid hormone | Metabolic disorders | Phase I demonstrated the compound is orally bioavailable in humans and appears to be safe and well tolerated (7/16) | |
Hutchison China MediTech Ltd.* (China) | HMPL-004 | A pro-inflammatory cytokine inhibitor | Mild to moderate ulcerative colitis | Phase II data showed it was well tolerated and had an equivalent drop in symptoms with the com-parator drug, Mesalazine (7/4)** | |
LAB International Inc.* (Canada) | Growth hormone releasing hormone analogue | Chronic kidney disease | Phase II data showed the drug induced a fivefold increase in endogenous growth hormone secretion and a near-doubling of circulating insulin-like growth factor compared to placebo (7/12) | ||
MedImmune Inc. (LSE:MDI; unit of AstraZeneca plc; UK) | Monoclonal antibody targeting the interleukin-5 receptor | Mild asthma | Phase I data suggested it successfully depleted eosinophils (7/23) | ||
Medivation Inc. (AMEX:MDX) | Dimebon | Neuroprotectant agent that's been on the market in Russia since 1983 | Huntington's disease | Began treatment of the first patient in a Phase II trial (7/30) | |
Mpex Pharmaceuticals Inc.* | MP-376 | An aerosol formulation of a powerful antibiotic | Cystic fibrosis | Started a Phase Ib trial (7/18) | |
Opko Health Inc. (AMEX:OPK) | Bevasiranib | siRNA drug | Wet age-related macular degeneration | Started a Phase III trial (7/11) | |
Progenics Pharmaceuticals Inc. (PGNX) and Wyeth Pharmaceuticals | MNTX | Oral methylnaltrexone; peripherally acting muopioid receptor antagonist | Opioid-induced constipation | Phase I data showed a majority of patients had a bowel movement after receiving the higher of two doses (7/20) | |
TargeGen Inc.* | TG100801 | Administered as an eye drop; designed to suppress VEGF-mediated leakage and additional kinase targets | Age-related macular degeneration | Started a Phase II trial (7/30) | |
Tercica Inc. (TRCA) | Increlex | Mecasermin [rDNA origin] injection | Short stature with primary insulin-like growth factor-1 deficiency | Completed patient enrollment in a Phase IIIb trial (7/20) | |
TransPharma Medical Ltd.* (Israel) | ViaDerm- hPTH | Transdermally delivered doses of hPTH | Osteoporosis | Phase I data showed a safety profile similar to the Forteo sub-cutaneous injection (7/16) | |
Uluru Inc. (AMEX:ULU) | Hydrogel | Nanoparticle wound dressing | Severely burned joints | Began a clinical study to evaluate the mobility of severely burned joints (7/26) | |
Notes: | |||||
* Privately held. | |||||
BLA = Biologics license application; FDA = Food and Drug Administration; IND = Investigational new drug application; NDA = New drug application; SPA = Special protocol assessment. | |||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | |||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSX = Toronto Stock Exchange. |